Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

ME. Caplin, M. Pavel, AT. Phan, JB. Ćwikła, E. Sedláčková, XT. Thanh, EM. Wolin, P. Ruszniewski, CLARINET Investigators

. 2021 ; 71 (2) : 502-513. [pub] 20201014

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026111

PURPOSE: In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved progression-free survival (PFS) vs placebo in patients with non-functioning intestinal or pancreatic neuroendocrine tumours (NETs). The aim of CLARINET open-label extension (OLE) (NCT00842348) was to evaluate long-term safety and efficacy of lanreotide in these patients. METHODS: Patients from the CLARINET study were eligible for the OLE if they had stable disease (irrespective of treatment group) or progressive disease (PD) (placebo-treated patients only). All patients in the OLE received lanreotide 120 mg every 28 days. Computed tomography or magnetic resonance imaging scans were conducted every 6 months and assessed locally for PD (the final scan was also assessed centrally). RESULTS: Overall, 89 patients took part in the OLE (lanreotide, n = 42; placebo, n = 47). Median (range) exposure to lanreotide in patients who received lanreotide in the core study and OLE (LAN-LAN group) was 59.0 (26.0-102.3) months. In this group, the overall incidences of adverse events (AEs) and treatment-related AEs were lower in the OLE than in the core study. Median [95% CI] PFS in the LAN-LAN group was 38.5 [30.9; 59.4] months. In placebo-treated patients with PD at the end of the core study, time to death or subsequent PD during the OLE was 19 [10.1; 26.7] months. CONCLUSIONS: This study provides new evidence on the long-term safety profile and sustained anti-tumour effects of lanreotide autogel/depot in indolent and progressive metastatic intestinal or pancreatic NETs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026111
003      
CZ-PrNML
005      
20211026133212.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12020-020-02475-2 $2 doi
035    __
$a (PubMed)33052555
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Caplin, Martyn E $u Department of Gastroenterology and Tumour Neuroendocrinology, Royal Free Hospital, London, UK. m.caplin@ucl.ac.uk
245    10
$a Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study / $c ME. Caplin, M. Pavel, AT. Phan, JB. Ćwikła, E. Sedláčková, XT. Thanh, EM. Wolin, P. Ruszniewski, CLARINET Investigators
520    9_
$a PURPOSE: In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved progression-free survival (PFS) vs placebo in patients with non-functioning intestinal or pancreatic neuroendocrine tumours (NETs). The aim of CLARINET open-label extension (OLE) (NCT00842348) was to evaluate long-term safety and efficacy of lanreotide in these patients. METHODS: Patients from the CLARINET study were eligible for the OLE if they had stable disease (irrespective of treatment group) or progressive disease (PD) (placebo-treated patients only). All patients in the OLE received lanreotide 120 mg every 28 days. Computed tomography or magnetic resonance imaging scans were conducted every 6 months and assessed locally for PD (the final scan was also assessed centrally). RESULTS: Overall, 89 patients took part in the OLE (lanreotide, n = 42; placebo, n = 47). Median (range) exposure to lanreotide in patients who received lanreotide in the core study and OLE (LAN-LAN group) was 59.0 (26.0-102.3) months. In this group, the overall incidences of adverse events (AEs) and treatment-related AEs were lower in the OLE than in the core study. Median [95% CI] PFS in the LAN-LAN group was 38.5 [30.9; 59.4] months. In placebo-treated patients with PD at the end of the core study, time to death or subsequent PD during the OLE was 19 [10.1; 26.7] months. CONCLUSIONS: This study provides new evidence on the long-term safety profile and sustained anti-tumour effects of lanreotide autogel/depot in indolent and progressive metastatic intestinal or pancreatic NETs.
650    12
$a protinádorové látky $x škodlivé účinky $7 D000970
650    _2
$a lidé $7 D006801
650    12
$a neuroendokrinní nádory $x farmakoterapie $7 D018358
650    12
$a nádory slinivky břišní $x farmakoterapie $7 D010190
650    _2
$a cyklické peptidy $x terapeutické užití $7 D010456
650    _2
$a somatostatin $x analogy a deriváty $7 D013004
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pavel, Marianne $u Department of Medicine, Division of Endocrinology and Diabetology, Universitätsklinikum Erlangen, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany
700    1_
$a Phan, Alexandria T $u Department of Hematology-Oncology, University of Texas Health Science Center at Tyler, Tyler, TX, USA $u Cancer Treatment Centers of America at South Eastern Regional Center, Atlanta, GA, USA
700    1_
$a Ćwikła, Jarosław B $u Department of Cardiology and Cardiac Surgery, School of Medicine, University of Warmia and Mazury, Olsztyn, Poland $u Diagnostic and Therapeutic Center - Gammed, Warsaw, Poland
700    1_
$a Sedláčková, Eva $u Department of Oncology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
700    1_
$a Thanh, Xuan-Mai Truong $u Medical Affairs, Ipsen Pharma, Boulogne-Billancourt, France
700    1_
$a Wolin, Edward M $u Tisch Cancer Institute at Mount Sinai and Icahn School of Medicine at Mount Sinai, New York, NY, USA $u Center for Carcinoid and Neuroendocrine Tumors, New York, NY, USA
700    1_
$a Ruszniewski, Philippe $u Division of Gastroenterology and Pancreatology, Beaujon Hospital, Clichy, France $u Université de Paris, Paris, France
710    2_
$a CLARINET Investigators
773    0_
$w MED00180215 $t Endocrine $x 1559-0100 $g Roč. 71, č. 2 (2021), s. 502-513
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33052555 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133218 $b ABA008
999    __
$a ok $b bmc $g 1714967 $s 1146618
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 71 $c 2 $d 502-513 $e 20201014 $i 1559-0100 $m Endocrine $n Endocrine $x MED00180215
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace